Pet CBD Market Projected at $600 Million in 2026 as Veterinary Acceptance Accelerates
This article contains affiliate links. If you purchase through our links, we may earn a commission at no extra cost to you.
The market for hemp-derived CBD products designed for companion animals is entering a new phase of growth in 2026, with analysts projecting the category will reach approximately $600 million in valuation this year before tracking toward a compound annual growth rate of 33% through the next decade. That trajectory, tracked by Future Market Insights in its most recent category assessment, positions pet CBD as one of the fastest-growing segments within the broader hemp-derived products industry.
The drivers are converging simultaneously: growing veterinary willingness to discuss CBD options with pet owners, expanding legislative protection for veterinarians in states like Maryland, improved product quality standards, and a consumer base that increasingly views pet wellness through the same framework as their own health decisions.
The $600 Million Market in Context
The pet CBD market’s current size needs context to be meaningful. At $600 million, the category represents a fraction of the overall pet care market in the United States — a market that Nielsen IQ estimates at approximately $150 billion annually. The penetration of CBD-specific products into pet spending is still relatively small, which is precisely why growth rate projections are so aggressive: the baseline is low and the ceiling is high.
The category has also matured structurally since its emergence following the 2018 Farm Bill. Early market entrants often offered minimal product differentiation, loose labeling, and limited quality documentation. The 2026 market looks different. Established brands now routinely provide full Certificate of Analysis documentation from ISO-accredited laboratories, publish batch-specific potency testing, and formulate products specifically for animal physiology rather than adapting human product lines.
The National Animal Supplement Council (NASC), which provides a voluntary quality assurance program for pet supplement brands, has seen increased adoption among CBD-specific pet product makers — a structural quality signal that is influencing purchasing decisions among veterinarians and informed consumers.
What’s Driving the Growth Trajectory
Three structural forces are supporting the market’s long-term growth projections:
Veterinary discussion is now legally protected in more states. Maryland’s unanimous legislative approval of a bill protecting veterinarians who discuss cannabis with pet owners is the most recent in a series of state-level protections. Colorado, California, and Oregon created similar frameworks in prior years. As more states extend this protection, the population of veterinarians willing to engage substantively with pet owners on CBD questions grows — and with it, the volume of consumer purchasing decisions that are informed by professional guidance.
Consumer research familiarity is deepening. The cohort of pet owners who began exploring CBD for their own use several years ago now brings direct personal experience to their decision-making for their animals. These consumers are more likely to evaluate Certificate of Analysis documentation, assess brand quality, and make informed purchases — which rewards the higher-quality end of the market.
Product formats have expanded. The 2026 pet CBD market includes soft chews, functional treats, topical products for skin and coat, and ingestible oils across a range of concentrations. The expansion of formats allows pet owners to select products that fit their animals’ preferences and their own ease of administration — reducing one of the historical friction points in the category.
The Regulatory Gap: Navigating Without FDA Oversight
The pet CBD market’s growth is occurring largely in the absence of specific federal regulatory oversight. Unlike human CBD products, which the FDA has at least acknowledged as a regulatory priority, pet CBD supplements operate under an even less structured federal framework. The FDA Center for Veterinary Medicine has issued general guidance that hemp-derived products for animals are not approved drugs and that therapeutic claims are not permitted — but formal product standards have not been established.
The absence of federal standards places the quality assurance burden on brands themselves and on voluntary certification programs like NASC’s. For pet owners, this means that the safeguards they benefit from in the human supplement market — even the limited ones — are even less present when purchasing products for their animals.
Navigating this environment effectively requires looking for products with third-party laboratory verification, transparent ingredient sourcing, and brands that operate within recognized voluntary quality frameworks.
These statements have not been evaluated by the Food and Drug Administration. CBD products for pets are not intended to diagnose, treat, cure, or prevent any disease. CBDworldnews.com reports on the CBD industry for informational and news purposes only. Nothing on this site constitutes veterinary or medical advice. Always consult a licensed veterinarian before introducing any new supplement to your pet’s routine.
Learn more:
